Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3098581 | 0.92 | P2RX3 (0.64) | P2RX3P2RX2 | |
| SCHEMBL3098049 | 0.86 | P2RX3 (0.74) | P2RX3P2RX2 | |
| SCHEMBL3092401 | 0.84 | P2RX3 (0.59) | P2RX3P2RX2 | |
| SCHEMBL13154094 | 0.84 | P2RX3 (0.58) | P2RX3P2RX2 | |
| SCHEMBL3094698 | 0.81 | P2RX3 (0.60) | P2RX3P2RX2 | |
| SCHEMBL3080019 | 0.81 | P2RX3 (0.57) | P2RX3P2RX2 | |
| SCHEMBL13154027 | 0.80 | P2RX3 (0.58) | P2RX3P2RX2 | |
| SCHEMBL13154022 | 0.80 | P2RX3 (0.58) | P2RX3P2RX2 | |
| SCHEMBL13154025 | 0.80 | P2RX3 (0.58) | P2RX3P2RX2 | |
| SCHEMBL13154031 | 0.79 | P2RX3 (0.57) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924566-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-7799796-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799796-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799796-B2 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20070049534-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049534-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
| US-20070049534-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | ROCHE PALO ALTO LLC | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049534-A1 | Diaminopyrimidines as P2X3 and P2X2/3 modulators | P2RX3, P2RX1, P2RX6 | P2RX3 1/4885P2RX2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.